Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
| Autor: | Simona Guerzoni, Nicoletta Brunelli, Simona Sacco, N. V. Latysheva, Paolo Martelletti, Raffaele Ornello, Carlo Baraldi, Alicia Alpuente, Patricia Pozo-Rosich, Marco Russo, Bruno Colombo, Calogera Butera, Antonio Russo, Giorgio Lambru, Anna Gryglas-Dworak, S. Cevoli, Marcin Straburzyński, Ruth Ruscheweyh, Andrea Negro, Anna Maria Miscio, Marcello Silvestro, Fayyaz Ahmed, Katharina Kamm, Licia Grazzi, Massimo Filippi, Elena Filatova, Fabrizio Vernieri, Antonio Santoro, Paola Torelli, Anna P. Andreou |
|---|---|
| Přispěvatelé: | Ornello, R., Ahmed, F., Negro, A., Miscio, A. M., Santoro, A., Alpuente, A., Russo, A., Silvestro, M., Cevoli, S., Brunelli, N., Vernieri, F., Grazzi, L., Baraldi, C., Guerzoni, S., Andreou, A. P., Lambru, G., Kamm, K., Ruscheweyh, R., Russo, M., Torelli, P., Filatova, E., Latysheva, N., Gryglas-Dworak, A., Straburzynski, M., Butera, C., Colombo, B., Filippi, M., Pozo-Rosich, P., Martelletti, P., Sacco, S., Institut Català de la Salut, [Ornello R] Neuroscience Section, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, 67100 L’Aquila, Italy. [Ahmed F] Department of Neurosciences, Hull University Teaching Hospitals, Hull, UK. [Negro A] Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant’Andrea Hospital, Sapienza University, 00189 Rome, RM, Italy. [Miscio AM, Santoro A] Unit of Neurology, Headache Center, Fondazione IRCCS ‘‘Casa Sollievo della Sofferenza’’, San Giovanni Rotondo, FG, Italy. [Alpuente A, Pozo-Rosich P] Unitat de Cefalea, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalees i Dolors Neurològics, Servei de Medicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos [ENFERMEDADES] Migranya - Efecte dels medicaments Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Migranya - Tractament Other subheadings::Other subheadings::/drug therapy [Other subheadings] law.invention Chronic Migraine Randomized controlled trial law OnabotulinumtoxinA Internal medicine Statistical significance medicine Gender difference Adverse effect Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders Primary::Migraine Disorders [DISEASES] Migraine Original Research Chronic migraine Men business.industry diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] medicine.disease Anesthesiology and Pain Medicine Propensity score matching Cohort Avaluació de resultats (Assistència sanitària) Observational study Neurology (clinical) business |
| Zdroj: | Pain and Therapy Scientia |
| ISSN: | 2193-651X 2193-8237 |
| Popis: | Migranya crònica; Diferència de gènere; OnabotulinumtoxinA Migraña crónica; Diferencia de género, OnabotulinumtoxinA Chronic migraine; Gender difference; OnabotulinumtoxinA Introduction Migraine is mostly a female disorder because of its lower prevalence in men. Less than 20% of patients included in the available studies on migraine treatments are men; hence, the evidence on migraine treatments might not apply to men. The aims of the present study were to provide reliable information on the effectiveness of onabotulinumtoxinA (BT-A) for chronic migraine in men and to compare clinical benefits between men and women. Methods We performed a pooled patient-level gender-specific analysis of real-life data on BT-A for chronic migraine of patients followed-up to 9 months. We reported the 50% responder rates during each BT-A cycle, defined as percentage of reduction in monthly headache days (MHDs) compared to baseline, along with 75% and 30% responder rates. We also reported the mean decrease in MHDs and in days of acute medication use (DAMs) during each BT-A cycle as compared to baseline. We also evaluated the reasons for stopping the treatment within the third cycle. Results We included an overall cohort of 2879 patients, 522 of whom (18.1%) were men. In men, 50% responder rates were 27.7% during the first BT-A cycle, 29.2% during the second, and 35.6% during the third cycle; in women, the corresponding rates were 26.6%, 33.5%, and 41.0%. In the overall cohort, responder rates did not differ between men and women during the first two cycles; during the third cycle, the distribution was different (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|